MRNA

SEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 719,456

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.31 to $25.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 719,915

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.10 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-009078 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 725,378

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.09 to $23.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-009068 · form4.xml · derivative · entry 2

LEE JENNIFER LING · CIK 0001675118 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,677

Underlying: Common Stock · 8,677 shares

Expires not disclosed

F2 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

SEC source: 0001127602-20-009068 · form4.xml · derivative · entry 1

LEE JENNIFER LING · CIK 0001675118 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,112

Underlying: Common Stock · 16,112 shares

Expires 2030-02-28

F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

SEC source: 0001127602-20-009046 · form4.xml · derivative · entry 1

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,022

Underlying: Common Stock · 179,022 shares

Expires 2030-02-28

F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

SEC source: 0001127602-20-008630 · form4.xml · derivative · entry 6

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 909,425

Underlying: Common Stock · 8,006 shares

Expires 2027-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F6 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

SEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 5

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.59 to $32.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 4

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.60 to $33.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 3

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,772

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.62 to $34.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 2

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,960

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.63 to $35.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-008630 · form4.xml · nonDerivative · entry 1

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,006

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-008174 · form4.xml · nonDerivative · entry 5

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,282,510

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.42 to $29.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-008174 · form4.xml · nonDerivative · entry 4

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,283,255

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-008174 · form4.xml · nonDerivative · entry 3

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,296,074

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-008174 · form4.xml · nonDerivative · entry 2

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,301,162

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-008174 · form4.xml · nonDerivative · entry 1

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,301,262

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $26.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-008173 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,722,648

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

SEC source: 0001127602-20-007602 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,056,530

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.36 to $19.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-007174 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,770

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001127602-20-007170 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 729,052

F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.96 to $18.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-007170 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,232,886

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-007170 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,953,216

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The Reporting Person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-006014 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,727,934

F4 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The reported disposition represents a bona fide charitable gift made by the reporting person.

SEC source: 0001127602-20-006018 · form4.xml · nonDerivative · entry 1

SAGAN PAUL · CIK 0001035440 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By: The Paul Sagan Revocable Trust

Disclosed balance after: 420,407

F1 · ownership.direct: Erwin Park LLC is an estate planning vehicle for the Reporting Person's family. The Chatham Trust is an irrevocable family trust for which the Reporting Person serves as a trustee. The Paul Sagan Revocable Trust is a revocable trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001127602-20-006014 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 740,098

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.86 to $19.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-005649 · form4.xml · nonDerivative · entry 2

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,066,530

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.90 to $19.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-005649 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,071,530

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.25 to $19.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 7

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,235,529

F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F8 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 6

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,955,859

F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F7 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The Reporting Person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 5

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,732,934

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

SEC source: 0001127602-20-004986 · form4.xml · nonDerivative · entry 1

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,302,510

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 4

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 751,144

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.31 to $23.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 752,924

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.25 to $22.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 753,724

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.19 to $21.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-004985 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,737,237

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

SEC source: 0001127602-20-003493 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,239,832

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-003493 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,964,465

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-003163 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 762,190

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-003163 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 762,290

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.08 to $20.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-002613 · form4.xml · nonDerivative · entry 2

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,335,805

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.10 to $23.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-002613 · form4.xml · nonDerivative · entry 1

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,336,705

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-002437 · form4.xml · nonDerivative · entry 3

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,076,530

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.98 to $21.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-002430 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 773,236

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.95 to $21.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-002437 · form4.xml · nonDerivative · entry 2

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,081,530

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.50 to $22.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-002437 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,081,915

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.47 to $22.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-002274 · form4.xml · nonDerivative · entry 1

Kim Lorence H. · CIK 0001643746 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,360,510

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to 23.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001127602-20-002273 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,742,113

F1 · kind: This sale was affected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.

SEC source: 0001127602-20-002157 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,242,270

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001127602-20-002157 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,966,903

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan.

F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.